Skip to content
Screener

Similar metrics at other companies

Credo Technology Group Holding Ltd logo
CRDOUnited States — Revenue
$314.12M+1,166%
Ameresco logo
AMRCUnited States — Revenue
$240.37M+3.3%
CBIZ logo
CBZUnited States — Revenue
$689.04M+52.2%
Alpha and Omega Semiconductor logo
AOSLUNITED STATES — Revenue
$2.15M+84.3%
Braze, Inc. logo
BRZEUnited States — Revenue
$115.51M+31.4%
Asana logo
ASANUnited States — Revenue
$120.32M+7.9%

Other financials

Income statement

See full
Revenue$51.4M+8.5%
Gross profit$20.7M+166%
Operating income-$15.1M+77.2%
Net income-$12.4M+68.6%
EPS (diluted)-$0.08+70.4%

Balance sheet

See full
Cash & equivalents$70.6M-73.8%
Total debt$176.7M-52.4%
Total equity$204.6M-23.0%
Total assets$603.7M-32.7%

Cash flow

See full
Operating cash flow$4.0M+139%
CapEx$370.0K-87.1%
Free cash flow$3.6M+128%

Valuation

See full
Market cap$918.96M+210%
Enterprise value$1.03B+158%
P/S4.4×+3.1×

Profitability

See full
Gross margin34.9%+4.4pp
Operating margin-56.1%-21.3pp
Net margin-37.1%-13.6pp
FCF margin-17.2%

Returns & leverage

See full
Return on equity-32.9%-9.4pp
Debt / equity0.9×-0.5×
Current ratio4.1×-1.1×

Where this comes from

Reported directly by Maravai LifeSciences Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Maravai LifeSciences Holdings, Inc.’s 10-Q, filed August 7, 2026.

Filed
Aug 7, 2026, 4:03 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001823239-26-000059
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Revenue$51,442$47,397$117,279$94,247
Cost of revenue30,79239,62962,92878,754
Gross profit20,6507,76854,35115,493
Operating expenses:
Selling, general and administrative32,07038,71561,16278,279
Research and development3,7024,8827,5919,770
Goodwill impairment30,44942,884
Restructuring(33)2,845

Item 1. Financial Statements

FAQ

What is Maravai LifeSciences Holdings, Inc.'s UNITED STATES — revenue?
Maravai LifeSciences Holdings, Inc. (MRVI) reported UNITED STATES — revenue of $30.9M in Q2 2026.
How has Maravai LifeSciences Holdings, Inc.'s UNITED STATES — revenue changed year-over-year?
Maravai LifeSciences Holdings, Inc.'s UNITED STATES — revenue increased by 2.0% year-over-year, from $30.3M to $30.9M.
What does UNITED STATES — revenue mean?
This metric represents the total revenue generated from sales of nucleic acid production and biologics safety testing products to customers located within the United States. It serves as a key indicator of the company's market penetration and demand for its life sciences research and therapeutic manufacturing solutions in the domestic market. Tracking this geographic revenue stream helps investors assess the company's reliance on the U.S. healthcare and biotechnology research landscape.

Ask your AI about Maravai LifeSciences Holdings, Inc.'s united states — revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude